Literature DB >> 7579490

Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer.

J D Iglehart1, B J Kerns, G Huper, J R Marks.   

Abstract

Ductal carcinoma in situ (intraductal carcinoma) of the breast is a commonly recognized and curable clinical entity. Patients with intraductal carcinoma are at risk to develop invasive breast cancer presumably due to a transition from the noninvasive to the invasive phase of growth. Primary breast malignancies commonly display both in situ and invasive phases of growth in the same tumor. In the current study, DNA content and alterations in the erbB-2 (HER-2/neu) oncogene product were examined simultaneously in both growth phases of primary breast cancers by image analysis. DNA content in the intraductal and invasive components of primary breast cancers were virtually identical (r = 0.979, p < 0.001). Quantitative image analysis was used to measure erbB-2 expression and categories of expression were related to copy number of the erbB-2 gene. Expression of erbB-2 was similar in both growth phases and implies identity of the erbB-2 genotype. The identity of DNA content suggests that the noninvasive and invasive phases within a single breast cancer are highly related. It is likely that erbB-2 gene number remains the same during progression from intraductal to invasive disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7579490     DOI: 10.1007/BF00689717

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  29 in total

1.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.

Authors:  M J van de Vijver; J L Peterse; W J Mooi; P Wisman; J Lomans; O Dalesio; R Nusse
Journal:  N Engl J Med       Date:  1988-11-10       Impact factor: 91.245

2.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

3.  Treatment of intraductal carcinoma with limited surgery: long-term follow-up.

Authors:  W J Gallagher; F C Koerner; W C Wood
Journal:  J Clin Oncol       Date:  1989-03       Impact factor: 44.544

4.  Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases.

Authors:  H Lacroix; J D Iglehart; M A Skinner; M H Kraus
Journal:  Oncogene       Date:  1989-02       Impact factor: 9.867

5.  The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen.

Authors:  A L Schechter; D F Stern; L Vaidyanathan; S J Decker; J A Drebin; M I Greene; R A Weinberg
Journal:  Nature       Date:  1984 Dec 6-12       Impact factor: 49.962

6.  Maintenance of p53 alterations throughout breast cancer progression.

Authors:  A M Davidoff; B J Kerns; J D Iglehart; J R Marks
Journal:  Cancer Res       Date:  1991-05-15       Impact factor: 12.701

7.  Prospective study of non-infiltrating carcinoma of the breast.

Authors:  R Ashikari; A G Huvos; R E Snyder
Journal:  Cancer       Date:  1977-02       Impact factor: 6.860

8.  Intraductal carcinoma of the breast: follow-up after biopsy only.

Authors:  D L Page; W D Dupont; L W Rogers; M Landenberger
Journal:  Cancer       Date:  1982-02-15       Impact factor: 6.860

9.  Breast carcinoma in situ. A retrospective review of 112 cases with a minimum 10 year follow-up.

Authors:  J A Sunshine; H S Moseley; W S Fletcher; W W Krippaehne
Journal:  Am J Surg       Date:  1985-07       Impact factor: 2.565

10.  Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms.

Authors:  M H Kraus; N C Popescu; S C Amsbaugh; C R King
Journal:  EMBO J       Date:  1987-03       Impact factor: 11.598

View more
  5 in total

1.  Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning.

Authors:  Min Yi; Thomas A Buchholz; Funda Meric-Bernstam; Isabelle Bedrosian; Rosa F Hwang; Merrick I Ross; Henry M Kuerer; Sheng Luo; Ana M Gonzalez-Angulo; Aman U Buzdar; W Fraser Symmans; Barry W Feig; Anthony Lucci; Eugene H Huang; Kelly K Hunt
Journal:  Ann Surg       Date:  2011-03       Impact factor: 12.969

2.  Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay.

Authors:  J P Vaughn; J D Iglehart; S Demirdji; P Davis; L E Babiss; M H Caruthers; J R Marks
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

3.  Cancer biomarker HER-2/neu in breast cancer in Indian women.

Authors:  Rajeev Singhai; Amit V Patil; Vinayak W Patil
Journal:  Breast Cancer (Dove Med Press)       Date:  2011-03-29

4.  Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.

Authors:  F Wärnberg; H Nordgren; L Bergkvist; L Holmberg
Journal:  Br J Cancer       Date:  2001-09-14       Impact factor: 7.640

5.  Comparison of Her-2, EGFR and cyclin D1 in primary breast cancer and paired metastatic lymph nodes: an immunohistochemical and chromogenic in situ hybridization study.

Authors:  Eun Yoon Cho; Jae Joon Han; Yoon-La Choi; Kyoung-Mee Kim; Young Lyun Oh
Journal:  J Korean Med Sci       Date:  2008-12-24       Impact factor: 2.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.